The Monjuvi therapy. Morphosys extends its lymphoma focus

Monjuvi, the CD19-targeting antibody therapy from MorphoSys, is approved in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma in the US. This product is driving the price of MorphoSys AG stock (ISIN DE0006632003).

Monjuvi is the drug name you see printed in a calm blue on a white infusion bag while the chemo ward hums quietly around you. The monoclonal antibody from MorphoSys is aimed at a very specific enemy in the blood of lymphoma patients: the CD19 antigen on B cells.

Positioning in lymphoma care

Monjuvi is the US trade name for tafasitamab, a humanized anti-CD19 monoclonal antibody co-developed by MorphoSys and Incyte for the treatment of diffuse large B-cell lymphoma, or DLBCL. It is used in adults whose DLBCL has relapsed or is refractory to prior systemic therapy and who are not eligible for autologous stem cell transplant.

The combination of Monjuvi with lenalidomide received accelerated approval from the US Food and Drug Administration in July 2020 for this indication, based on the phase 2 L-MIND trial. In Europe, the same molecule is marketed under the name Minjuvi, where the European Medicines Agency granted conditional marketing authorization in 2021 for relapsed or refractory DLBCL in adults ineligible for autologous stem cell transplant. MorphoSys patient information

Mechanism and treatment routine

Monjuvi’s active substance tafasitamab is an Fc-enhanced antibody that binds to CD19, a transmembrane protein widely expressed on B cells, including malignant DLBCL cells. By engaging CD19, tafasitamab promotes direct cell death and enhances immune effector mechanisms such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.

In practical terms, that means the drug is administered intravenously in a series of infusions, with nurses hooking up clear lines while patients watch the drip rate and check the clock. In the L-MIND regimen, Monjuvi is combined with lenalidomide for up to 12 cycles, followed by Monjuvi monotherapy until disease progression or unacceptable toxicity. The schedule typically starts with loading doses in the first cycle and then moves to every two weeks after cycle four. FDA approval release

Data from the L-MIND study

The pivotal L-MIND trial enrolled adult patients with relapsed or refractory DLBCL who had received one to three prior systemic regimens and were ineligible for autologous stem cell transplant. The study evaluated tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy in responding patients.

In the published data, the combination achieved an overall response rate of around 55%, with a complete response rate near 37% and a median duration of response exceeding two years. These numbers matter when patients and oncologists sit together in small consultation rooms, comparing options on printouts with survival curves. The safety profile featured manageable hematologic toxicities such as neutropenia and thrombocytopenia, and infusion-related reactions typically occurred in early cycles. Blood journal L-MIND paper

Competitive landscape and positioning

Diffuse large B-cell lymphoma has become a crowded therapeutic space, with CAR-T cell therapies, polatuzumab-based regimens and emerging bispecific antibodies vying for attention in treatment guidelines. Monjuvi, as an antibody with conventional infusion logistics, fits into the niche for patients who cannot access or tolerate autologous stem cell transplant or CAR-T procedures.

MorphoSys CEO Jean-Paul Kress has repeatedly framed Monjuvi as a cornerstone in the company’s commercial portfolio, even as newer assets such as pelabresib attract headline attention in myelofibrosis. For a mid-sized German biotech, the ability to bring a lymphoma therapy from antibody discovery platforms in Planegg-Martinsried to infusion chairs in US and European hospitals is strategically significant. MorphoSys quarterly update

Pricing, access and reimbursement

As a specialty oncology product, Monjuvi is priced in the high-cost range typical for biologic therapies, with list prices in the United States reflecting its targeted use and complex manufacturing. Exact net prices vary depending on payer contracts, discounts and patient assistance programs, and are rarely visible to patients beyond copay figures.

Access in the US is supported by Incyte’s patient support services, which help deal with reimbursement and logistics for eligible adults with relapsed or refractory DLBCL. In Europe, Minjuvi is subject to country-specific health technology assessments and reimbursement negotiations, with national agencies weighing clinical benefit against budget impact when deciding on coverage for lymphoma centers.

Manufacturing and supply considerations

Producing tafasitamab requires biologics manufacturing facilities capable of stable monoclonal antibody expression, purification and rigorous quality control. That complexity is mostly invisible to patients, but it defines lead times and inventory planning for hospitals ordering Monjuvi vials.

MorphoSys, which historically focused on antibody discovery and early development, relies on its partnership with Incyte for commercial operations and broader manufacturing scale in North America. For European supply of Minjuvi, MorphoSys coordinates with its partners and contract manufacturers to ensure continuous availability in hematology clinics, where delays translate directly into scheduling headaches for oncologists.

Regulatory status and label details

In the US, the Monjuvi label specifies combination use with lenalidomide for adults with relapsed or refractory DLBCL, including DLBCL arising from low-grade lymphoma, after one prior line of therapy, ineligible for autologous stem cell transplant. The accelerated approval pathway requires ongoing confirmatory data to maintain the indication.

In the EU, Minjuvi’s conditional marketing authorization focuses on adults with relapsed or refractory DLBCL who are not candidates for autologous stem cell transplant, using tafasitamab plus lenalidomide followed by tafasitamab monotherapy. National regulators and health authorities monitor real-world data as well as longer-term follow-up from L-MIND and related studies when reviewing the product’s benefit-risk profile.

Perspectives from clinicians

Hematologists such as Professor Martin Dreyling in Munich or US lymphoma experts like Dr. Gilles Salles have discussed CD19-targeted therapies as part of evolving treatment algorithms for aggressive B-cell lymphomas, even if they are not always speaking specifically about Monjuvi in publicly available commentaries. Their focus lies on balancing efficacy, toxicity and patient comorbidities.

From the clinician’s perspective, a therapy like Monjuvi offers another tool when standard R-CHOP chemotherapy or subsequent regimens have failed, and when transplant or CAR-T options are off the table. As always in oncology, case selection, careful monitoring and shared decision-making with patients matter as much as the molecular details on the drug label.

Context and MorphoSys stock

For MorphoSys, Monjuvi is both a revenue stream and a proof point that its antibody discovery technologies can anchor a commercial hematology franchise. Alongside its pipeline of epigenetic and immuno-oncology candidates, the lymphoma product helps to stabilize the business model between R&D spending and partner revenues.

On Xetra, MorphoSys AG stock trades in euros under ISIN DE0006632003, with Monjuvi and Minjuvi sales figures featuring regularly in quarterly reports as management explains the trajectory of its oncology portfolio to investors.

Monjuvi key facts

• Product: Monjuvi (tafasitamab)
• Manufacturer: MorphoSys AG
• Category: Accessory/Spare part – oncology therapy within hematology portfolio
• Market launch: US approval July 2020; EU approval as Minjuvi 2021
• MSRP / Price: High-cost specialty biologic therapy; actual prices subject to payer contracts and country reimbursement
• Availability: Approved in the US as Monjuvi and in Europe as Minjuvi for adults with relapsed or refractory DLBCL ineligible for autologous stem cell transplant
• Target group: Adult patients with relapsed or refractory diffuse large B-cell lymphoma who have received prior systemic therapy and are not candidates for autologous stem cell transplant
• Highlight / USP: Fc-enhanced anti-CD19 monoclonal antibody used with lenalidomide, offering a non-transplant option in a defined DLBCL population